1. Scrip
  2. >>R&D

Wave’s Huntington Drugs Wipe Out As Trials Run Aground

WVE-120102 And WVE-120101 Fail To Show Benefit

 
• By Alaric DeArment

The company now turns to its next-generation Huntington drug, WVE-003.

Amazing, perfect wave - Image
Wave is moving on to next-generation drug WVE-003 after its first-generation Huntington drugs failed. • Source: Shutterstock

WAVE Life Sciences Ltd. is banking on its next-generation asset for Huntington disease (HD) after the failure of a clinical trial program of two earlier-generation drugs, which itself closely follows Roche Holding AG’s discontinuation of its own HD trial. Wave is hoping that the new drug’s improved preclinical pharmacology will raise the odds of success.

The Cambridge, MA-based company announced 29 March that data from the Phase Ib/IIa PRECISION-HD2 study of WVE-120102 and the PRECISION-HD1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

More from Scrip

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

In partnership with

Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.